173 Stories, most recent news story added Fri Nov 27, 8:09 am ET
THE FBI's failure to see clear warning signs in the Fort Hood case revives the ques tion of whether it's up to the task of countering terrorism. Before his murderous rampage, Maj. Nidal Malik Hasan was exchanging e-mails with a radical Yemen-base...
A vast array of establishment and expert sources do not believe this episode was really resolved.
As expected, Human Genome Sciences has applied for federal regulatory approval to market its new treatment for hepatitis C.
Will Cel-Sci's flu drug last longer than its other fly-by-night projects?
ALISO VIEJO, Calif.----AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and twelve months ended September 30, 2009.
Yes, the Bush administration held off on prosecuting terrorists. AG Eric Holder's criticism of this shows a dangerous disconnect from reality.
By United Press International UPI Almanac for Saturday, Nov. 21, 2009.
Soligenix, Inc. , formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has formed a consortium to develop thermostable technology to advance RiVax and other rapidly acting vaccines.
The discovery Wednesday morning of an unknown powder leaking from a package on the dock of the downtown Yerington Post Office caused a shutdown of Main Street and and both local Postal facilities and also serves as a reminder to postal patrons to be careful how well they seals packages, especially if a powder is involved.
Remember the days and weeks just after 9/11? Remember the anxiety - or downright fear - of wondering whether there would be another attack like the ones at the World Trade Center and the Pentagon?
FDA delayed the approval of Human Genome's anthrax drug, ABthrax.
Human Genome Sciences said Monday that approval of its experimental anthrax drug hit a delay as regulators asked the firm for more information about the treatment.
Human Genome Sciences Inc. said Monday the Food and Drug Administration will not approve the company's anthrax treatment until it receives additional information on the potential drug.
'The Monster at Our Door'
Human Genome Sciences faces FDA regulatory delay on anthrax treatment Human Genome Sciences - Food and Drug Administration - Terrorism - Anthrax - Biological and Chemical
ROCKVILLE, Md.----Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration relating to the Company’s Biologics License Application requesting the approval of raxibacumab for use in the treatment of inhalational anthrax.